| Aspirin is an effective antiplatelet drug with proven benefit in the primary and secondary prevention of coronary heart disease.But the absolute risk of recurrent vascular events among patients taking aspirin remains relatively high,suggesting that the antiplatelet effects of aspirin may not be equivalent.Some patients were aspirin resistance and clinical trials have showed that aspirin resistance have been associated with worse clinical outcome.The mechanisms of aspirin resistance are complicated and not completely understood.Potential causes may include genetic polymorphisms.Cyclooxygenase-2,as a induced enzyme,may regenerate after inhibited by aspirin,it has also hypothesized that cyclooxygenase-2 may contribute to aspirin resistance,the study was to investigate the association between the cyclooxygenase-2 765G/C gene polymorphism and aspirin resistance in patients of coronary heart disease.Objective:To investigate the association between the cyclooxygenase-2 765G/C gene polymorphism and aspirin resistance in patients of coronary heart disease.Methods:264 patients with coronary heart disease who had taken aspirin (100mg/d) for more than 20 days were detected platelet aggregation induced by adenosine diphosphate(ADP) and collagen(COL).They were devided into aspirin resistance(AR) group or aspirin semiresistance(ASR) group and aspirin sensitive (AS) group.The gene types were determined with polymerase chain reaction and restricted fragment length polymorphism.Result:The frequency of genotype is GG(55.6%) GC(33.3%) CC(11.1%) in AR/ASR group and GG(70.8%) GC(25%) CC(4.2%) in AS group(P=0.16); The frequency of C allele is 27.8%in AR/ASR group and 16.7%in AS group(P= 0.097).There is no significant difference for both genotype and C allele between two groups.Conclusion:The above findings suggest that cyclooxygenase-2 765G/C gene polymorphism may not be associated with aspirin resistance in coronary heart disease. |
PDF Full Text Request